- Sona Nanotech (SONA) has provided an update on its rapid test development programs
- Currently, the company is developing tests for concussions and bovine tuberculosis
- Sona is developing a way to test for biomarkers to screen for mild concussions and is moving on to the next phase of the project
- The company is also working on a bovine tuberculosis test with a group of Canadian and UK companies
- Sona Nanotech is a nanotechnology life sciences firm that has developed ways to manufacture various types of gold nanoparticles
Sona Nanotech (SONA) has provided an update on its rapid test development programs.
Sona uses a proprietary biocompatible gold nanorod (GNR) technology to develop rapid diagnostic tests and biologic reagents. Currently, the company is developing tests for concussions and bovine tuberculosis.
Sona is advancing a research and development program to better understand the proprietary GNR manufacturing technology. The goal is to identify the most promising advanced biomedical applications for the technology.
To accomplish this, Sona plans to partner with leaders in the bioengineering and nanotechnology fields to conduct a series of experiments and studies.
There is some concern within the medical community that the usual method for preparing other GNRs may be toxic and could cause potential negative health impacts. However, Sona has developed a unique process for manufacturing GNRs that does not use cetrimonium bromide, a substance well-known to be toxic.
The company will continue to strengthen its IP portfolio to become a leader in the use of GNRs for medical applications.
Sona’s concussion test for mild traumatic brain injury will aim to detect a series of biomarkers enabling the test to be used to screen for mild concussions. The next phase of the project will take up to six months.
Sona’s bovine tuberculosis (bTB) test is being developed with a group of companies as part of a Canada/UK industrial research and development program.
So far, testing has identified several biomarkers that are able to differentiate whether the bacteria present is due to an ongoing infection or the result of vaccination.
David Regan, CEO of Sona Nanotech, commented,
“Sona has made good progress across its portfolio of rapid tests […] The experiments and studies to be conducted under this long-term R&D effort have the potential to open new, important medical markets for our innovative technology and add value to the business.”
Sona Nanotech is a nanotechnology life sciences firm that has developed ways to manufacture various types of gold nanoparticles.
Sona Nanotech Inc. (SONA) is down 3.13 per cent, trading at $0.31 per share as of 10:58 am ET.